The Next Episode | What 13 Years of DSCSA Teach Us About NDC-12 and Pharmaceutical Interoperability
The Transactions Haven’t Changed. The Network Has. Flying home from the HDA Traceability Seminar last week, I saw some news from Philadelphia that put much of what we had spent the previous few days discussing […]
When Distribution Models Change Faster Than Controls: GLP-1, DTC, and the New Pharmaceutical Risk Landscape
Within this slide deck, you can explore how GLP-1 demand, telehealth, digital pharmacies, and direct-to-consumer distribution are reshaping the pharmaceutical supply chain and creating new patient safety and security challenges. Rx-360’s Ryan Kelly, Interim CEO […]
The BIOSECURE Act and the Quiet Work Ahead for Pharmaceutical Supply Chains
The BIOSECURE Act did not arrive with ceremony. It arrived embedded in the National Defense Authorization Act, debated largely in abstractions, and passed with little public attention. But for pharmaceutical and biotechnology companies operating global […]
Direct-to-Patient Pharmaceutical Programs
The pharmaceutical landscape is evolving rapidly, and one of the most transformative shifts is the rise of direct-to-patient (D2P) distribution. As manufacturers seek to bypass traditional channels and deliver medications straight to patients’ doors, the […]